|
Active substance |
Darolutamide |
|
Holder |
Bayer SA-NV |
|
Status |
Running |
|
Indication |
the treatment of adult men with metastatic hormone sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy. |
|
Public documents |
|
|
Last update |
25/09/2025 |
Nubeqa
Last updated on